Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Two-way Crossover Drug-drug Interaction Study to Assess the Effect of Laquinimod 0.6 mg on the Pharmacokinetics and Pharmacodynamics of Ethinylestradiol and Levonorgestrel in Healthy Young Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Laquinimod (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Huntington's disease; Multiple sclerosis; Uveitis; Wet age-related macular degeneration
- Focus Pharmacokinetics
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 06 Sep 2018 Results published in the European Journal of Clinical Pharmacology
- 26 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.